JSM 2011 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.


516 *	Wed, 8/3/2011, 10:30 AM - 12:20 PM	CC-D233
Issues in Adaptive Clinical Trials 1 — Contributed Papers
Biopharmaceutical Section
Chair(s): Rima Izem, U.S. Food and Drug Administration/CDER
10:35 AM	Adaptive Blinded Sample Size Adjustment for Comparing Two Normal Means: A Mostly Bayesian Approach — Andrew Montgomery Hartley, PPD
10:50 AM	Proposal for a Two-Stage Adaptive Dose-Response Trial Design Using Repeated Measures Data — Anjela Tzontcheva, Merck Research Laboratories ; Susan Huyck, Merck Research Laboratories
11:05 AM	A Three-Part Adaptive Design with POC and Dose-Finding for Induction Regimen and Dose-Finding for Maintenance Regimen for an Immunology Trial — Usha Barai, Merck Research Laboratories
11:20 AM	Adaptive Design for Bioequivalence Clinical Trials — Fengjuan Xuan, Merck & Co., Inc. ; Ferdous Gheyas, Merck & Co., Inc.
11:35 AM	Adaptive Clinical Trial Design and Simulation of a Phase II Migraine Headache Proof-of-Concept Study Using Adaptive Design Explorer — Inna Perevozskaya, Pfizer Inc. ; Jihao Zhou, Pfizer Inc. ; Pamela D. Garzone, Pfizer Inc. ; Phil Stanley, Pfizer Inc. ; John P. Huggins, Pfizer Inc. ; Gilbert Y. Wong, Pfizer Inc. ; Ronald G. Menton, Pfizer Inc.
12:05 PM	Martingale-Based Estimators Following Group Sequential/Adaptive Designs — Venkata Goteti, Merck & Co., Inc. ; Rongqi Chen, University of California at Davis ; Navdeep Boparai, Merck & Co., Inc.
12:05 PM	Floor Discussion

2011 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.